SCHEMBL4884359

SCHEMBL4884359

CN1C(=O)C(C)(C)c2cc(C(=O)CCl)ccc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
CDY1; CDY1B Q9Y6F8 1/20 0.46
GAA P10253 2/20 0.46
TSHR P16473 1/20 0.46
MAPT P10636 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
TP53 P04637 1/20 0.42
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
PKM P14618 1/20 0.40
LMNA P02545 1/20 0.40
IP6K1 Q92551 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6450148 0.87 CBX7 (0.45) CBX7CDYL2CDYLCDY1; CDY1BGAA
SCHEMBL9205601 0.83 ALDH1A1 (0.47) CBX7CDYL2CDYLCDY1; CDY1BMAPT
SCHEMBL3935379 0.82 IP6K1 (0.52) MAPTMEN1KMT2ATP53PDE4A
SCHEMBL17231387 0.82 MEN1 (0.47) MAPTMEN1KMT2AHPGDTP53
SCHEMBL31348132 0.82 IP6K1 (0.52) MAPTMEN1KMT2ATP53PDE4A
SCHEMBL6746180 0.80 HDAC1 (0.57) CBX7CDYL2CDYLCDY1; CDY1BGAA
SCHEMBL7432121 0.79 MEN1 (0.42) MAPTMEN1KMT2AALDH1A1TP53
SCHEMBL3931904 0.78 CASP3 (0.54) MAPTMEN1KMT2AALDH1A1TP53
SCHEMBL9366946 0.78 MAPT (0.44) CBX7CDYL2CDYLCDY1; CDY1BGAA
SCHEMBL9206539 0.77 MEN1 (0.45) GAAMAPTMEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269246-A1 METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER PFIZER INC 2008-10-30 US disclosed
EP-1757292-A1 Method of treating ocd and tic disorders Pfizer Products Inc. (US) 2007-02-28 EP disclosed
EP-1633361-A1 ANXIETY TREATMENTS WITH ZIPRASIDONE Pfizer Products Inc. (US) 2006-03-15 EP disclosed
EP-1626722-A1 METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE Pfizer Products Inc. (US) 2006-02-22 EP disclosed
EP-1626723-A1 TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS Pfizer Products Inc. (US) 2006-02-22 EP disclosed
US-20050038036-A1 Stabilization patient; antidepressant; psychological disorders; mood cycles PFIZER INC 2005-02-17 US disclosed
US-20050014764-A1 Method for enhancing cognition using ziprasidone PFIZER INC 2005-01-20 US disclosed
US-20050004138-A1 Anxiety treatments with ziprasidone PFIZER INC 2005-01-06 US disclosed
WO-2004100955-A1 ANXIETY TREATMENTS WITH ZIPRASIDONE PFIZER PRODUCTS INC. (US) 2004-11-25 WO disclosed
WO-2004100957-A1 TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS PFIZER PRODUCTS INC. (US) 2004-11-25 WO disclosed
EP-0985414-A2 Method of treating glaucoma and ischemic retinopathy Pfizer Products Inc. (US) 2000-03-15 EP disclosed
EP-0931547-A1 Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions Pfizer Products Inc. (US) 1999-07-28 EP disclosed
EP-0901789-A1 Method of treating tourette's syndrome Pfizer Products Inc. (US) 1999-03-17 EP disclosed
EP-0497852-B1 BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM BOEHRINGER MANNHEIM GMBH (DE) 1995-12-20 EP disclosed
EP-0497852-A1 BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM. BOEHRINGER MANNHEIM GMBH (DE) 1992-08-12 EP disclosed
EP-0281309-B1 PIPERAZINYL-HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 1991-12-27 EP disclosed
WO-1991006545-A1 BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM BOEHRINGER MANNHEIM GMBH (DE) 1991-05-16 WO disclosed
US-4883795-A Piperazinyl-heterocyclic compounds PFIZER INC. (US) 1989-11-28 US disclosed
US-4831031-A Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity PFIZER INC. (US) 1989-05-16 US disclosed
EP-0281309-A1 Piperazinyl-heterocyclic compounds PFIZER INC. (US) 1988-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038036-A1 Stabilization patient; antidepressant; psychological disorders; mood cycles MC2R, NR3C1, CRH CBX7 3376/4885CDYL2 3042/4885CDYL 2613/4885
US-20050014764-A1 Method for enhancing cognition using ziprasidone DBH, RAP1A, GABRR1 CBX7 4556/4885CDYL2 3156/4885CDYL 2559/4885
US-20080269246-A1 METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER GABBR1, GABRR1, GABBR2 CBX7 3779/4885CDYL2 2726/4885CDYL 1928/4885
US-20050004138-A1 Anxiety treatments with ziprasidone NPSR1, AVPR1B, SLC39A3 CBX7 1958/4885CDYL2 1926/4885CDYL 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.